PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence , and provided a clinically significant survival advantage for up to 3 years after treatment compared with those of the control group : ( 1 ) the recurrence-free rate increased from 50 % to 63 % , and ( 2 ) time to recurrence at the 36th percentile was postponed by 78 % .